James Peyer Sells 3,105 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder James Peyer sold 3,105 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $8.59, for a total value of $26,671.95. Following the completion of the transaction, the insider directly owned 158,254 shares of the company’s stock, valued at approximately $1,359,401.86. This trade represents a 1.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

James Peyer also recently made the following trade(s):

• On Tuesday, December 9th, James Peyer sold 3,507 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $7.96, for a total transaction of $27,915.72.
• On Friday, December 5th, James Peyer sold 16,295 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $11.50, for a total transaction of $187,392.50.
• On Thursday, December 4th, James Peyer sold 5,000 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $9.06, for a total transaction of $45,300.00.

Sensei Biotherapeutics Stock Performance

Shares of SNSE stock opened at $9.00 on Friday. Sensei Biotherapeutics, Inc. has a fifty-two week low of $5.00 and a fifty-two week high of $18.35. The stock’s fifty day moving average price is $9.82 and its two-hundred day moving average price is $8.63. The company has a market cap of $11.34 million, a PE ratio of -0.47 and a beta of 0.32.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its quarterly earnings data on Friday, November 14th. The company reported ($3.62) earnings per share for the quarter, topping the consensus estimate of ($4.11) by $0.49. On average, equities analysts predict that Sensei Biotherapeutics, Inc. will post -1.17 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on SNSE shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Sensei Biotherapeutics in a report on Monday. HC Wainwright cut shares of Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.